{
    "clinical_study": {
        "@rank": "3079", 
        "arm_group": [
            {
                "arm_group_label": "Tacrolimus/Methotrexate", 
                "arm_group_type": "Experimental", 
                "description": "Tacrolimus D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to therapeutic drug monitoring(TDM) (10-20ng/ml)\nMethotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
            }, 
            {
                "arm_group_label": "Cyclosporine/Methotrexate", 
                "arm_group_type": "Active Comparator", 
                "description": "Cyclosporine D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)\nMethotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to compare efficacy and safety of tacrolimus/methotrexate with\n      cyclosporine/methotrexate for graft versus host disease prophylaxis in paediatric allogeneic\n      hematopoietic stem cell transplantation patients."
        }, 
        "brief_title": "Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Graft vs Host Disease", 
        "condition_browse": {
            "mesh_term": "Graft vs Host Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of hematological malignancy\n\n          -  Age under 18 years old\n\n          -  Serum bilirubin less than 1.5 X upper limit of normal\n\n          -  Aspartate transaminase, Alanine transaminase less than 2.5 X upper limit of normal\n\n          -  Alkaline phosphatase less than 2.5 X upper limit of normal\n\n          -  Serum creatinine less than 1.5 X upper limit of normal\n\n          -  Agrees to participate, and informed consent signed\n\n        Exclusion Criteria:\n\n          -  Evidence of HIV infection\n\n          -  Documented uncontrolled disease (infections)\n\n          -  Prior transplantation (hematopoietic stem cell or solid organs)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01788501", 
            "org_study_id": "SNUCP_001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tacrolimus/Methotrexate", 
                "description": "D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cyclosporine/Methotrexate", 
                "description": "D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)", 
                "intervention_name": "Cyclosporine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Tacrolimus/Methotrexate", 
                    "Cyclosporine/Methotrexate"
                ], 
                "description": "D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push", 
                "intervention_name": "Methotrexate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine", 
                "Methotrexate", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 13, 2013", 
        "location": [
            {
                "contact": {
                    "email": "onskydream1@hanmail.net", 
                    "last_name": "Kim", 
                    "phone": "82-10-7650-2656"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Hospital"
                }, 
                "investigator": {
                    "last_name": "HyoungJin Kang", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "onskydream1@hanmail.net", 
                    "last_name": "Kim", 
                    "phone": "82-10-7650-2656"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Asan Medical Center"
                }, 
                "investigator": {
                    "last_name": "KyoungNam Ko", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "onskydream1@hanmail.net", 
                    "last_name": "Kim", 
                    "phone": "82-10-7650-2656"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "investigator": {
                    "last_name": "KeonHee Yoo", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease in Paediatric Patients", 
        "overall_contact": {
            "email": "onskydream1@hanmail.net", 
            "last_name": "MyeongGyu Kim", 
            "phone": "82-2-2072-0335"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University College of Pharmacy", 
            "last_name": "JungMi Oh, Pharm.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Overall grade I graft-versus-host disease denoted stage 1 to 2 skin involvement with no liver or gut involvement. Overall grade II graft-versus-host disease  denoted stage 3 skin involvement or stage 1 liver or gut involvement. Overall grade III graft-versus-host disease  denoted stage 4 skin involvement or stage 2 to 4 liver or gut involvement without graft-versus-host disease as a major contributing cause of death. And Overall grade IV graft-versus-host disease denoted stage 4 skin involvement or stage 2 to 4 liver or gut involvement with graft-versus-host disease as a major contributing cause of death.", 
            "measure": "incidence of grade II-IV acute graft versus host disease", 
            "safety_issue": "No", 
            "time_frame": "day 100 post transplantation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01788501"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Hyoung Jin Kang", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Fever would be categorized as fever occured before engraftment and after engraftment. If microbiologically documented, pathogen would be specified.", 
                "measure": "incidence of infection", 
                "safety_issue": "Yes", 
                "time_frame": "day 100 post transplantation"
            }, 
            {
                "description": "adverse drug reactions would be measured by Common Terminology Criteria for Adverse Events v3. And for determinating the likelihood of whether an adverse drug reaction is actually due to the drug, Naranjo algorithm would be used", 
                "measure": "incidence of adverse drug reactions", 
                "safety_issue": "Yes", 
                "time_frame": "day 100 post transplantation"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}